Company CSL Limited

Company CSL Limited

CSL

AU000000CSL8

Pharmaceuticals

Analysts' Consensus

Equities

CSL

AU000000CSL8

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for CSL Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for CSL Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
273.3 ^AUD	-1.85%		+1.41%	-4.66%

03:31am	Australian shares tumble as miners, energy stocks fall; BHP Group tanks	RE
Apr. 24	CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	CI

CSL Limited is an Australia-based biotechnology company. The Companyâs areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyâs segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Number of employees: 32,065

AUD in Million	2022	Weight	2023	Weight	Delta
CSL Behring 69.8 %	11,857	81.4 %	13,811	69.8 %	+16.48%
CSL Seqirus 15.3 %	2,708	18.6 %	3,019	15.3 %	+11.52%
CSL Vifor 14.9 %	-	-	2,957	14.9 %	-

AUD in Million	2022	Weight	2023	Weight	Delta
United States 49.3 %	7,065	48.5 %	9,757	49.3 %	+38.10%
Rest of World 21.4 %	2,776	19.1 %	4,236	21.4 %	+52.59%
Australia 7.9 %	1,409	9.7 %	1,554	7.9 %	+10.23%
Germany 6.5 %	1,077	7.4 %	1,292	6.5 %	+19.93%
China 5.9 %	1,027	7.0 %	1,158	5.9 %	+12.79%
United Kingdom 5.4 %	822	5.6 %	1,066	5.4 %	+29.68%
Switzerland 3.7 %	388	2.7 %	725	3.7 %	+86.90%

Managers	Title	Age	Since
Paul McKenzie CEO	Chief Executive Officer	58	19-05-31
Joy Carolyn Linton DFI	Director of Finance/CFO	59	20-09-30
Mark Hill CTO	Chief Tech/Sci/R&D Officer	62	20-09-30
William Mezzanotte CTO	Chief Tech/Sci/R&D Officer	66	18-09-30
Andrew Nash CTO	Chief Tech/Sci/R&D Officer	-	06-10-31
Andrew Cuthbertson BRD	Director/Board Member	70	97-02-28
Mark Dehring IRC	Investor Relations Contact	-	-
Kate Priestman PRN	Corporate Officer/Principal	-	23-09-10
Ken Lim PRN	Corporate Officer/Principal	50	12-12-31
Bill Campbell PRN	Corporate Officer/Principal	64	13-12-31

Members of the board	Title	Age	Since
Carolyn Hewson BRD	Director/Board Member	69	19-12-08
Brian McNamee PSD	President	68	90-06-30
Alison Watkins BRD	Director/Board Member	61	21-08-18
Andrew Cuthbertson BRD	Director/Board Member	70	97-02-28
Megan Clark BRD	Director/Board Member	66	16-02-15
Marie McDonald BRD	Director/Board Member	68	13-08-13
Sam Lewis BRD	Director/Board Member	-	Dec. 31
Duncan Maskell BRD	Director/Board Member	63	21-08-17
Paul McKenzie CEO	Chief Executive Officer	58	19-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	483,093,257	480,846,726 ( 99.53 %)	0	99.53 %

Name	Equities	%	Valuation
State Street Global Advisors Trust Co. 1.107 %	5,349,487	1.107 %	1 005 M $
Colonial First State Investments Ltd. 0.9797 %	4,734,581	0.9797 %	889 M $
Commonwealth Superannuation Corp. (Investment Management) 0.6784 %	3,278,217	0.6784 %	616 M $
Netwealth Investments Ltd. 0.5316 %	2,568,812	0.5316 %	483 M $
Australian Foundation Investment Co. Ltd. (Invt Mgmt) 0.5030 %	2,431,000	0.5030 %	457 M $
BetaShares Capital Ltd. 0.3329 %	1,608,787	0.3329 %	302 M $
AMP Capital Investors Ltd. 0.2738 %	1,322,973	0.2738 %	249 M $
Argo Investments Ltd. (Investment Management) 0.2594 %	1,253,509	0.2594 %	235 M $
State Street Global Advisors Ltd. 0.2178 %	1,052,335	0.2178 %	198 M $
Australian Eagle Asset Management Pty Ltd. 0.2019 %	975,763	0.2019 %	183 M $

Name	Equities	%	Valuation
SILVERCREST ASSET MANAGEMENT GROUP INC. 0.006264 %	60,545	0.006264 %	6 M $
Boston Common Asset Management LLC 0.004533 %	43,811	0.004533 %	4 M $
Domini Impact Investments LLC 0.003321 %	32,100	0.003321 %	3 M $
Yousif Capital Management LLC 0.001762 %	17,030	0.001762 %	2 M $
RhumbLine Advisers LP 0.001472 %	14,227	0.001472 %	1 M $
Budapest Fund Management Co. Ltd. 0.000507 %	4,901	0.000507 %	460 302 $
SVB Wealth LLC 0.000405 %	3,919	0.000405 %	368 072 $
GAMMA Investing LLC 0.000171 %	1,652	0.000171 %	155 156 $
Ametos Invest GmbH 0.000124 %	1,200	0.000124 %	112 704 $
PNC Investments LLC 0.000017 %	161	0.000017 %	15 121 $

Name	Equities	%	Valuation
CARA THERAPEUTICS, INC. 13.53%	7,396,770	13.53%	6,731,061 $

CSL Ltd.

655 Elizabeth Street

3000, Melbourne

+61 3 9389 1911

http://www.csl.com.au

Name	Category and Sector
CSL Behring LLC CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA.	Biotechnology
CSL Behring AG CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The private company is based in Bern, Switzerland.	Biotechnology
CSL Behring UK Ltd. CSL Behring UK Ltd. Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring UK Ltd. is a private company that manufactures and supplies plasma therapies. The company is based in Haywards Heath, UK. The British company was founded in 1916 by Emil von Behring.	Pharmaceuticals: Major
CSL Behring GmbH CSL Behring GmbH Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring GmbH is a German company that actively collaborates to develop special programs and activities for patients with rare diseases. The private company is based in Marburg, Germany. The CEOs of the company are Lutz Guenter Bonacker, Michael Schröder, Craig Shelanskey.	Pharmaceuticals: Major
CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG is a German pharmaceutical company that manufactures pharmaceutical products. The private company is based in Marburg, Germany. The company was founded in 2004. The CEO is Craig Shelanskey.	Pharmaceuticals: Major
CSL Plasma GmbH CSL Plasma GmbH Medical/Nursing ServicesHealth Services CSL Plasma GmbH provides plasma collection and donation services. It specializes in the collection, testing, and management of plasma taken from blood donors. It focuses on the use of plasma as a key ingredient for products crucial to treating patients suffering from hemophilia, shock or trauma, immune deficiencies, and other blood disorders. It operates through its testing laboratories, collection facilities, and logistics centers. The company is headquartered in Marburg, Germany.	Medical/Nursing Services
CSL Finance GmbH CSL Finance GmbH Financial ConglomeratesFinance Part of CSL Ltd., CSL Finance GmbH is a German company that provides investment services. The company is based in Marburg, Germany. The CEOs are Antje Michel, Dieter Engstfeld, John Andrew Goodman Levy. The private company was founded in 2014.	Financial Conglomerates
CSL Behring Recombinant Facility AG CSL Behring Recombinant Facility AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring Recombinant Facility AG is a Swiss biotherapeutics company that develops and delivers innovative therapies to improve patients' lives. The private company is based in Bern, Switzerland and has a manufacturing site there. The company's portfolio includes a wide range of recombinant and plasma-derived products.	Biotechnology
CSL Behring Lengnau AG

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

180.7 USD

Average target price

199.4 USD

Spread / Average Target

+10.36%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-21.76%	29.48B
UCB	+56.78%	25.43B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	15.59B
INCYTE CORPORATION	-18.49%	11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.75B
INNOVENT BIOLOGICS, INC.	-8.19%	7.99B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals